TLS in Tumors May Predict Immunotherapy Benefit in NSCLC : v

New data indicate that tertiary lymphoid structures could predict which patients with advanced non-small cell lung cancer will benefit most from immunotherapy.

Related Keywords

Barzin Nabet , Genentech Oncology Biomarker Development , Society For Immunotherapy Of Cancer , Oncology Biomarker Development , Lung Cancer , Ung Carcinoma , Ancer Lung , Non Small Cell Lung Cancer , Nsclc , Biologic Therapy , Immunotherapy , Tumor , Cancer , Alignant Neoplasia , Arcinoma , Tissue , Chemotherapy , Lung , Biomarker , Iological Marker , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Clinical Research , Clinical Trials , Linical Studies ,